Care 4-Fold?
Does Spasticity Itself Raise the Cost of Stroke
Care 4-Fold?
To the Editor:
The report from Lundstrom et al 1 headlines a relationship between spasticity and higher direct costs of stroke care over the first year after onset. The authors seem to be putting the cart's contents, 1 of which is spasticity, before the horse of sensorimotor impairment. The authors used a modified Ashworth Score of Ն1 in any 1 of 7 arm and leg joints as the measure of spasticity. The modified Ashworth Score is a 6-point ordinal scale of resistance to passive movement across a joint, which can arise from reflexive clasp-knife resistance and from changes in connective tissues of the joint associated with severity of paresis, nonuse, and contracture. It is often used in studies, but its validity and reliability may be less than necessary to reflect a physiologically meaningful measure. 2 Clinicians involved in the care of patients with chronic stroke would not consider a modified Ashworth Score in any 1 joint of Ͻ3 to suggest a clinically important problem. No evidence exists that the modified Ashworth Score cutoff used for this study's retrospective, databasedriven findings could be detrimental after stroke. So what underlies the relationship described?
The authors found a significantly higher National Institutes of Health Stroke Scale score in the group considered to have any degree of spasticity. It would seem, then, that they would want to examine for a correlation between cost of care and level of impairment based on the National Institutes of Health Stroke Scale. They did show that poorer modified Rankin Scale scores (which intermix aspects of impairment and disability) were significantly related to higher costs. If indeed, greater resistance to passive movement across a singe joint has a relationship to cost, the primary relationship is probably to the degree of sensorimotor impairment that induces greater disability and, in turn, higher in-hospital costs from complications of greater impairment such as immobility.
The discussion from the authors seems to repudiate the primacy of their correlation. If "our study does not provide evidence that spasticity as such is responsible for the (4-fold) increase of costs" and "spasticity reflects a more severe motor disorder," how can the authors suggest that their data offer, at best, a baseline for "the cost-effectiveness of interventions, including botulinum toxin" . . . ? This particular intervention is likely to drive up costs if injected into patients with a modified Ashworth Score Ͻ3 but will not alter sensorimotor impairments. From a healthcare priority point of view, their findings suggest the need for more outpatient physiotherapy, which was provided to only 4% of their subjects. A rehabilitation intervention to maintain range of motion, prevent painful contractures and dystonic postures, and to improve motor control and skills might reduce disability, costs, and burden of care for those who are most impaired by paresis.
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